This statement is provided in response to the December 1990 US Food and Drug Administration (FDA) approval of labelling for a second Haemophilus influenzae type b conjugate vaccine, PRP-OMP (Table 1) for administration to infants as young as 2 months of age. The following recommendatios supercede previous American Academy of Pediatrics guidelines for the use of H influenzae type b conjugate vaccines.

This content is only available via PDF.